ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Evolving Standards of Care

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

on: April 21, 2025In: Evolving Standards of Care
MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

In this Q&A, Dr. Luis E. Raez and nurse practitioner Beth Sandy discuss recently reported MARIPOSA data in the context of current standard of care and provide best practices for therapeutic selection and patient education. Read more

Subcutaneous Amivantamab Leads to Unexpected OS Improvement vs. IV Dosing in Refractory, EGFR+ Advanced NSCLC

Fred Gebhart
on: June 25, 2024In: Evolving Standards of Care, Meeting News
Subcutaneous Amivantamab Leads to Unexpected OS Improvement vs. IV Dosing in Refractory, EGFR+ Advanced NSCLC

Dr. Natasha Leighl said the findings of PALOMA-3 show subcutaneous dosing offers other advantages, including reduced adverse events. Read more

KRYSTAL-12 Supports Previous Evidence Showing Adagrasib is Superior to Docetaxel in Pretreated Advanced KRAS-mutated NSCLC

Fred Gebhart
on: June 25, 2024In: Evolving Standards of Care, Meeting News
KRYSTAL-12 Supports Previous Evidence Showing Adagrasib is Superior to Docetaxel in Pretreated Advanced KRAS-mutated NSCLC

Dr. Tony Mok said the results of the phase III KRYSTAL-12 trial reinforce adagrasib as an effective second-line treatment option for this patient population. Read more

LAURA Trial Defines Role of EGFR-directed Therapy in Unresectable Stage III NSCLC

Erin Jungmeyer
on: June 11, 2024In: Evolving Standards of Care, Meeting News
LAURA Trial Defines Role of EGFR-directed Therapy in Unresectable Stage III NSCLC

Primary results from the study, presented by Dr. Suresh Ramalingam, showed osimertinib offers a significant improvement in progression-free survival following chemoradiotherapy. Read more

ADRIATIC Demonstrates Meaningful Improvements in OS, PFS in Patients with Limited-stage SCLC

Erin Jungmeyer
on: June 11, 2024In: Evolving Standards of Care, Meeting News
ADRIATIC Demonstrates Meaningful Improvements in OS, PFS in Patients with Limited-stage SCLC

As the first study to establish the role of immunotherapy in this setting, Dr. David R. Spigel says consolidation durvalumab will become the new standard of care for this population. Read more

Glecirasib Shows Promise in Treating Advanced Lung Cancer Harboring KRAS G12C Mutations

Erin Jungmeyer
on: June 11, 2024In: Evolving Standards of Care
Glecirasib Shows Promise in Treating Advanced Lung Cancer Harboring KRAS G12C Mutations

With only 5% of patients stopping treatment due to treatment-related adverse events, lead author Yuankai Shi, MD, says glecirasib may help improve patient compliance with oral therapy. Read more

Mounting Evidence Supporting Neoadjuvant ChemoIO Means Surgeons Must Adapt

Ke-Neng Chen, MD
on: May 21, 2024In: Evolving Standards of Care
Mounting Evidence Supporting Neoadjuvant ChemoIO Means Surgeons Must Adapt

In a two-part commentary, Dr. Ke-Neng Chen discusses how surgeons must adjust in light of recent clinical trials, beginning with a discussion of the challenges of TNM staging. Read more

More Than Ever, Surgeons Must Collaborate to Ensure Patients Receive Appropriate Care

Ke-Neng Chen, MD
on: May 21, 2024In: Evolving Standards of Care
More Than Ever, Surgeons Must Collaborate to Ensure Patients Receive Appropriate Care

As thoracic surgery in the management of NSCLC evolves, Dr. Ke-Neng Chen highlights the importance of avoiding unnecessary treatments and using a multidisciplinary approach. Read more

A New Treatment Option for Early-Stage ALK+ NSCLC: Adjuvant Alectinib

Narjust Florez, MD
on: May 21, 2024In: Evolving Standards of Care
A New Treatment Option for Early-Stage ALK+ NSCLC: Adjuvant Alectinib

In part 2 of their interview, Drs. Narjust Florez and Benjamin Solomon dig deeper into the implications of the ALINA trial, discussing endpoints, toxicities, and future directions. Read more

Increased Biomarker Uptake Needed to Further Realize Potential of Precision Medicine

Christian Rolfo, MD, PhD, MBA, Drhc
+more
on: May 07, 2024In: Evolving Standards of Care
Increased Biomarker Uptake Needed to Further Realize Potential of Precision Medicine

Drs. Christian Rolfo and Valeria Denninghoff contend that data show improvements in outcomes from personalized treatment may have stalled and that increased testing for driver genes alterations is needed. Read more

Could Precision Oncology Evolve to Treat Cancer Before It Develops?

Laila C. Roisman, PhD
+more
on: May 07, 2024In: Evolving Standards of Care
Could Precision Oncology Evolve to Treat Cancer Before It Develops?

Drs. Laila Roisman and Nir Peled envision a future where artificial intelligence elevates personalized medicine in ways once thought impossible. Read more

‹1234567›»

SEARCH ILCN

Archives

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy